Raloxifene Hydrochloride Tablet, Coated
Product Images NDC 72241-010

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 72241-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Modavar Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Modavar-cont-label-60mg-100-tab (Modavar Cont Label 60mg 100 Tab)

This is a description of a medication called Raloxifene Hydrochloride, distributed by Modavar in the form of tablets. The package includes 100 tablets containing 80g of Raloxifene Hydrochloride, and should be stored at temperatures between 15° and 30° Celsius. The usual administered dose is not specified and requires consulting with a physician. The package label contains standard security and safety precautions to prevent misuse, and it is manufactured by Gadl Pramacuicls LLC. The packaging also includes an issued date of 08/2021 and a product number of noc 72241-010-05.*

FDA Label Image

Modavar-cont-label-60mg-1000-tab (Modavar Cont Label 60mg 1000 Tab)

This appears to be a label of Raloxifene Hydrochloride Tablets, USP manufactured by Modavar. The label includes information on dosage, usage, and warnings. The tablets are used to treat osteoporosis in postmenopausal women. The label also includes the manufacturer's contact information.*

FDA Label Image

Modavar-cont-label-60mg-2000-tab (Modavar Cont Label 60mg 2000 Tab)

FDA Label Image

Modavar-cont-label-60mg-30-tab (Modavar Cont Label 60mg 30 Tab)

This is a description of a prescription medication called Raloxifene Hydrochloride in tablet form. The tablets are being sold in a package containing 30 units by a manufacturer named Hotavar Pharmaceuticals L. The medication should be kept away from children and should not be used if the packaging is missing or damaged. The text mentions a recommended adult dosage and instructions for use contained in the packaging. The medication is made by the manufacturer Gadia Promacoutcas L in India.*

FDA Label Image

Raloxifene-spl-figure-1 (Raloxifene Spl Figure 1)

Total hip mean percentage change from baseline is being reported for subjects who received either a placebo or Raloxifene Hydrochloride in studies NA and EUS for a time period of 24 months. In addition, the same measurement is being reported for subjects who received placebo, Raloxifene Hydrochloride, and CE in a study called INT; this study focused on women who had hysterectomies. No useful information can be obtained from the text for "Ruletene Hydeochoride" and "S Biptene Hysrochorive".*

FDA Label Image

Raloxifene-spl-strc.jpg (Raloxifene Spl Strc)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.